GFA
8783
Pluszero
5132
GreenBee
3913
Metaplanet
3350
Chiome Bioscience
4583
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.70%54.98B | 5.61%287.88B | 1.36%103.96B | 11.33%64.87B | 2.02%65.52B | 12.64%53.53B | 6.87%272.58B | 6.17%102.57B | -2.06%58.27B | 19.28%64.22B |
Cost of revenue | -4.61%41.58B | 4.43%218.89B | 0.87%76.1B | 8.65%48.72B | -0.37%50.48B | 12.79%43.59B | 8.08%209.6B | 4.58%75.44B | -0.41%44.84B | 21.53%50.67B |
Gross profit | 34.73%13.4B | 9.55%68.99B | 2.71%27.86B | 20.32%16.15B | 10.97%15.03B | 11.99%9.95B | 3.04%62.98B | 10.88%27.13B | -7.20%13.42B | 11.55%13.55B |
Operating expense | 7.33%14.3B | 3.35%56.26B | 8.31%15.05B | 4.86%13.86B | 0.44%14.03B | -0.28%13.32B | 5.39%54.44B | 0.15%13.89B | 3.02%13.22B | 8.52%13.96B |
Staff costs | ---- | 2.91%18.69B | ---- | ---- | ---- | ---- | 3.18%18.16B | ---- | ---- | ---- |
Selling and administrative expenses | ---- | 11.07%4.66B | ---- | ---- | ---- | ---- | 24.80%4.19B | ---- | ---- | ---- |
-Selling and marketing expense | ---- | 40.18%1.25B | ---- | ---- | ---- | ---- | 10.55%891M | ---- | ---- | ---- |
-General and administrative expense | ---- | 3.21%3.41B | ---- | ---- | ---- | ---- | 29.30%3.3B | ---- | ---- | ---- |
Research and development costs | ---- | 1.26%4.11B | ---- | ---- | ---- | ---- | -5.41%4.06B | ---- | ---- | ---- |
Depreciation and amortization | ---- | 0.35%3.17B | ---- | ---- | ---- | ---- | -2.35%3.16B | ---- | ---- | ---- |
-Depreciation | ---- | 0.35%3.17B | ---- | ---- | ---- | ---- | -2.35%3.16B | ---- | ---- | ---- |
Rent and land expenses | ---- | -0.44%1.58B | ---- | ---- | ---- | ---- | 12.48%1.59B | ---- | ---- | ---- |
Other operating expenses | ---- | 3.32%24.05B | ---- | ---- | ---- | ---- | 7.02%23.28B | ---- | ---- | ---- |
Operating profit | 73.44%-896M | 49.08%12.74B | -3.17%12.82B | 1,043.00%2.29B | 342.31%1.01B | 24.64%-3.37B | -9.82%8.54B | 24.94%13.24B | -87.73%200M | 42.46%-416M |
Net non-operating interest income (expenses) | 2.51%-194M | 29.41%-60M | 6.51%507M | -25.38%-163M | -1.99%-205M | 13.48%-199M | -214.86%-85M | 4.85%476M | -4.84%-130M | -64.75%-201M |
Non-operating interest income | 178.26%64M | 14.91%848M | 8.33%754M | 142.11%46M | 92.31%25M | 130.00%23M | 15.67%738M | 15.61%696M | 26.67%19M | 0.00%13M |
Non-operating interest expense | 16.22%258M | 10.33%908M | 12.27%247M | 40.27%209M | 7.48%230M | -7.50%222M | 45.92%823M | 48.65%220M | 7.19%149M | 58.52%214M |
Net investment income | 36.06%1.2B | 227.95%751M | 57.45%-294M | 82.44%-75M | -34.86%241M | -10.03%879M | -59.54%229M | -218.43%-691M | -210.34%-427M | 428.57%370M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 1.27B | -94.47%63M | -91.39%63M | 0 | 0 | 0 | 308.60%1.14B | 72.24%732M | 110.92%31M | 0 |
Income from associates and other participating interests | ||||||||||
Special income (charges) | -219.05%-67M | 433.03%2.31B | 56.72%-87M | 594.85%2.7B | -454.43%-280M | -112.57%-21M | 166.62%433M | 62.43%-201M | 1,652.00%388M | 319.44%79M |
Less:Other special charges | 219.05%67M | -241.28%-2.78B | -58.89%-286M | -594.85%-2.7B | 331.65%183M | 112.57%21M | -642.67%-814M | -614.29%-180M | -1,652.00%-388M | -319.44%-79M |
Less:Write off | ---- | 23.36%470M | -2.10%373M | --0 | ---- | ---- | -23.80%381M | --381M | --0 | ---- |
Other non-operating income (expenses) | 134.78%108M | -127.34%-38M | -184.42%-65M | -97.73%1M | -200.00%-20M | 2,400.00%46M | -49.08%139M | -73.72%77M | 500.00%44M | 122.22%20M |
Income before tax | 153.20%1.42B | 51.54%15.76B | -5.03%12.94B | 4,292.59%4.74B | 609.59%744M | 16.25%-2.67B | 4.14%10.4B | 23.74%13.62B | -93.12%108M | 81.82%-146M |
Income tax | 168.62%374M | 40.66%4.41B | -12.94%3.25B | 5,078.57%1.45B | 328.33%257M | 20.32%-545M | 3.50%3.14B | 27.37%3.73B | -94.88%28M | 173.17%60M |
Net income | 149.22%1.05B | 56.25%11.34B | -2.03%9.69B | 4,016.25%3.29B | 334.78%486M | 15.15%-2.12B | 4.40%7.26B | 22.40%9.89B | -92.18%80M | 71.29%-207M |
Net income continuous operations | 149.25%1.05B | 56.25%11.35B | -2.04%9.69B | 4,017.50%3.29B | 336.41%487M | 15.14%-2.12B | 4.41%7.26B | 22.42%9.89B | -92.18%80M | 71.43%-206M |
Noncontrolling interests | 228.57%27M | 4.55%138M | -30.90%123M | 142.17%35M | -97.67%1M | -250.00%-21M | -40.00%132M | 24.48%178M | -284.44%-83M | 65.38%43M |
Net income attributable to the company | 148.38%1.02B | 57.20%11.21B | -1.50%9.56B | 1,885.98%3.26B | 294.40%486M | 15.79%-2.1B | 5.87%7.13B | 22.35%9.71B | -83.21%164M | 66.53%-250M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 148.38%1.02B | 57.20%11.21B | -1.50%9.56B | 1,885.98%3.26B | 294.40%486M | 15.79%-2.1B | 5.87%7.13B | 22.35%9.71B | -83.21%164M | 66.53%-250M |
Gross dividend payment | ||||||||||
Basic earnings per share | 148.42%22.44 | 57.19%247 | -1.51%210.81 | 1,883.70%71.81 | 294.56%10.72 | 15.79%-46.34 | 5.86%157.13 | 22.34%214.05 | -83.19%3.62 | 66.55%-5.51 |
Diluted earnings per share | 148.42%22.44 | 57.19%247 | -1.50%210.81 | 1,886.02%71.7898 | 294.40%10.7123 | 15.79%-46.34 | 5.86%157.13 | 22.36%214.025 | -83.21%3.6148 | 66.54%-5.5103 |
Dividend per share | 0 | 50.00%75 | 127.27%50 | 0 | -10.71%25 | 0 | 0.00%50 | -12.00%22 | 0 | 12.00%28 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |